Treatment of acute cerebral infarction with PGI2--evaluating the clinical effect and observation of dynamic changes in plasma TXB2 and 6-keto PGF1 alpha levels

18 patients with acute cerebral infarction were randomly subdivided into two groups: PGI2-treated group (11 cases) and low-molecular-weight Dextran-treated group (7 cases). Dosage of PGI2 was 2-5 ng/kg/min intravenous drip. Infusion was started within 72 hours after the onset of symptoms. The data showed that the plasma 6-keto-PGF1 alpha levels were increased, the plasma TXB2 levels, MAR as well as the scores of neurological deficit were decreased in the PGI2-treated group. The clinical improvement in PGI2-treated group is better than that in the dextran-treated group.